Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
Rev. Soc. Bras. Med. Trop
;
52: e20180211, 2019. tab, graf
Artigo
em Inglês
| LILACS
| ID: biblio-1003136
ABSTRACT
Abstract Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine antimoniate administration has fewer adverse effects and can be as effective and safe. We describe 12 patients treated with intralesional meglumine antimoniate: seven with primary and five with recurrent lesions. The majority (11/12) met all cure criteria after 1-7 sessions of meglumine antimoniate administration (1-5 mL). Adverse effects comprised mainly of local pain and edema. Intralesional meglumine antimoniate administration could be an excellent alternative treatment for uncomplicated CL; however, controlled clinical trials are needed to test the efficacy and safety thereof.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Leishmaniose Cutânea
/
Antimoniato de Meglumina
/
Antiprotozoários
Limite:
Adulto
/
Feminino
/
Humanos
/
Lactente
/
Masculino
Idioma:
Inglês
Revista:
Rev. Soc. Bras. Med. Trop
Assunto da revista:
Medicina Tropical
Ano de publicação:
2019
Tipo de documento:
Artigo
País de afiliação:
Colômbia
Instituição/País de afiliação:
Universidad CES/CO
/
Universidad de Antioquia/CO
Similares
MEDLINE
...
LILACS
LIS